Filing Flows › Harmony Biosciences Holdings (HRMY) › Guidance history
Harmony Biosciences Holdings (HRMY) guidance history: what it guided and what it reported
Harmony Biosciences Holdings gave guidance in 3 earnings releases on file since Jul 16, 2026.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q3 2027 | $269M (Nov 4, 2026) | — | to be reported | — |
| FY2026 | $1.0B–$1.0B (Jul 16, 2026) → reaffirmed $1.0B–$1.0B (Aug 4, 2026) | — | to be reported | — |
The latest quarter
Harmony Biosciences Holdings, Q3 2026: revenue $269M (+12% year over year), operating margin 20.2%, net earnings $48.2M, operating cash flow $76.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does Harmony Biosciences Holdings beat its guidance?
Harmony Biosciences Holdings gave guidance in 3 earnings releases on file since Jul 16, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.